RUBY - ルビウス・セラピュ―ティクス (Rubius Therapeutics Inc.) ルビウス・セラピュ―ティクス

 RUBYのチャート


 RUBYの企業情報

symbol RUBY
会社名 Rubius Therapeutics Inc (ルビウス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Rubius Therapeutics Inc is a biotechnology company that develops cellular therapies for cancer and enzyme deficiency diseases. The Company develops Red-Cell Therapeutics (RCT) products using red platform. RCT is a red blood cell-based therapy for applications in cancer enzyme replacement therapies and autoimmune disease and tolerance induction. Its RCT product candidate is designed to provide various attributes which include broad therapeutic applications predictable bio-distribution and advantageous tolerability. It is initially focused on advancing RCT product candidates for patients suffering from rare diseases cancer and autoimmune diseases based on three modalities - cellular shielding potent cell-cell interaction and tolerance induction. Its product candidates in rare diseases include RTX-134 for the treatment of phenylketonuria (PKU) RTX-134 followed by RTX-Uricase and RTX-CBS for the treatment of chronic refractory gout symptomatic homocystinuria.   ルビウス・セラピュ―ティクスは米国のバイオ医薬品企業。主に重症患者のための赤血球治療薬の開発に従事する。同社の候補薬はフェニルケトン尿症、ホモシスチン尿症、慢性不応性痛風、急性ポルフィリン症、固形腫瘍、血液がん、自己免疫疾患などの治療に使用される。本社所在地はマサチュ―セッツ州ケンブリッジ。   Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.
本社所在地 325 Vassar Street Suite 1A Cambridge MA 02139 USA
代表者氏名 David R. Epstein David R. Epstein
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-679-9600
設立年月日 41365
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 83人
url www.rubiustx.com
nasdaq_url https://www.nasdaq.com/symbol/ruby
adr_tso
EBITDA EBITDA(百万ドル) -72.29900
終値(lastsale) 17.01
時価総額(marketcap) 1344514677.03
時価総額 時価総額(百万ドル) 1354
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 1432.92
当期純利益 当期純利益(百万ドル) -73.79000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rubius Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $15.1M to $44.4M. Higher net loss reflects Research and Development - Balancing increase from $7.3M to $19.9M (expense) Stock-based Compensation in SGA increase from $3.5M to $15.5M (expense) General and Administrative - Balancing increase from $1.9M to $6.6M (expense).

 RUBYのテクニカル分析


 RUBYのニュース

   Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright 23rd Annual Global Investment Conference in September 2021  2021/09/01 13:00:00 Intrado Digital Media
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that the Companys executive management team will participate in the Morgan Stanley 19 th Annual Global Healthcare Conference on September 9-13, 2021, and the H.C. Wainwright 23 rd Annual Global Investment Conference on September 14, 2021.
   Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer  2021/08/30 12:00:00 Intrado Digital Media
CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced the appointment of Jim Jogerst as chief business officer. He will oversee business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius overall corporate strategy.
   Rubius Therapeutics EPS misses by $0.06  2021/08/09 12:05:47 Seeking Alpha
   Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update  2021/08/09 12:00:00 Intrado Digital Media
First Patient Dosed with RTX-240 in Combination with KEYTRUDA ® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors
   The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight  2021/08/08 14:03:32 Benzinga
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week. BeyondSpring Inc. (NASDAQ: BYSI ) was among the biggest biopharma gainers of the week, with the stock reacting to a positive late-stage readout for its lung cancer treatment combo. The stock ended the week with a gain of about 128%. Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA ), however, was not as fortunate, as the stock lost about one-fifth of its market cap following mixed results from a pivotal trial of its RNAi therapeutic candidate nedosiran in primary hyperoxaluria 1. The market reacted negatively to earnings from vaccine companies Moderna, Inc. (NASDAQ: MRNA ) and Novavax, Inc. (NASDAQ: NVAX ). Moderna''s results, although outstanding, elicited negative reaction, while a lack of update about U.S. approval of Novavax'' vaccine sent its shares tumbling on Friday.
   Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy  2021/07/15 12:00:00 Intrado Digital Media
Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody
   Rubius Therapeutics doses first patient in RTX-240 cancer study  2021/06/23 20:07:51 Seeking Alpha
   Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors  2021/06/23 20:01:00 Wallstreet:Online
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination
   Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference  2021/05/20 00:00:00 BioSpace
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.
   Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting  2021/05/19 21:02:00 Wallstreet:Online
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting (aAPC)
   Rubius Therapeutics doses first patient in RTX-240 cancer study  2021/06/23 20:07:51 Seeking Alpha
   Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Advanced Solid Tumors  2021/06/23 20:01:00 Wallstreet:Online
CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that the first patient has been dosed in a new Phase 1 arm of the ongoing Phase 1/2 clinical trial of RTX-240 in combination
   Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference  2021/05/20 00:00:00 BioSpace
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.
   Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting  2021/05/19 21:02:00 Wallstreet:Online
CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics, today announced that the Company will present a Trials in Progress poster presentation for its lead artificial antigen-presenting (aAPC)
   Abbot Financial Management, Inc. Buys Rubius Therapeutics Inc, PIMCO Active Bond ETF, iShares ...  2021/05/13 18:38:36 GuruFocus
Related Stocks: RUBY , IEMG , CTAS , CRM , XLC , COST , BOND , BAND , SEDG , BMY , TD ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ルビウス・セラピュ―ティクス RUBY Rubius Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)